• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Wrigley, E
    Verspaget, H W
    Jayson, Gordon C
    McGown, Alan T
    Affiliation
    CRC Department of Drug Development, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester M20 4BX, United Kingdom.
    Issue Date
    2000-12
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND AND PURPOSE: Regimens containing platinum drugs continue to be amongst the most effective therapies for ovarian cancer. However, despite high initial response rates most patients relapse and die of their disease. Elevation of metallothionein has been implicated as a mechanism by which tumour cells become resistant to platinum anticancer drugs, although most of these studies have been carried out in vitro. This study was carried out to determine whether metallothionein expression was associated with response or survival in patients with epithelial ovarian cancer. METHODS: Metallothionein was determined by radioimmune assay using frozen ovarian tumour tissue taken either before or following cytotoxic chemotherapy. RESULTS: An increase in expression of metallothionein was seen in tumour tissue from patients who had undergone cytotoxic chemotherapy, although this did not attain significance. However, a preliminary study using biopsy material from the same patient, taken both before and after chemotherapy, showed a statistically significant increase in metallothionein. An analysis of these data showed that the level of metallothionein expression was not associated with survival or response. CONCLUSION: These data do not support the hypothesis that metallothionein expression is a determinant of response in ovarian cancer. There is some preliminary evidence from the study of paired samples which indicates that cytotoxic chemotherapy may increase metallothionein expression. An increase in metallothionein was also seen in the study using unmatched biopsies although this did not attain statistical significance, due in part to the large inter-patient variability in expression of this protein.
    Citation
    Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. 2000, 126 (12):717-21 J. Cancer Res. Clin. Oncol.
    Journal
    Journal of Cancer Research and Clinical Oncology
    URI
    http://hdl.handle.net/10541/86676
    DOI
    10.1007/PL00008477
    PubMed ID
    11153145
    Type
    Article
    Language
    en
    ISSN
    0171-5216
    ae974a485f413a2113503eed53cd6c53
    10.1007/PL00008477
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy.
    • Authors: Woolston CM, Deen S, Al-Attar A, Shehata M, Chan SY, Martin SG
    • Issue date: 2010 Nov 1
    • Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.
    • Authors: Yang F, Gao B, Chen W, Du E, Liang Y, Hu X, Yang X
    • Issue date: 2018 Oct
    • Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
    • Authors: Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, Zabel M
    • Issue date: 2005 Sep
    • Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    • Authors: Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
    • Issue date: 2003 Jan 15
    • Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
    • Authors: Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA
    • Issue date: 2012 May
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.